Porownywarka

Matrixyl vs GHK-Cu side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

MatrixylGHK-Cu

Udostępnij porównanie peptydów

Wlasciwosc	Matrixyl	GHK-Cu
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	Palmitoyl Pentapeptide-4, Pal-KTTKS	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Cosmetic use; extensively studied Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Collagen production, anti-aging, skin firmness	Skin rejuvenation, wound healing, hair growth, anti-aging
Jak dziala	Matrixyl is described as Pal-KTTKS, a palmitoylated form of a five-amino-acid collagen fragment. The KTTKS segment is presented as a matrikine-style signal associated with extracellular-matrix turnover, while the palmitoyl tail is used to improve compatibility with topical delivery through the outer skin barrier. The supplied evidence distinguishes this collagen-signaling model from muscle-targeting wrinkle approaches.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typowe dawkowanie	Limited community data available · See research protocols · Topical (serums, creams)	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Dawkowanie z badań	3-8% in formulations · 8-12 weeks for visible results, ongoing use · Topical (serums, creams)	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typowy czas trwania	8-12 weeks for visible results; ongoing use reported	Varies by application
Podanie	Topical skin application in serums or creams	Subcutaneous injection or topical application
Timing	Morning or as directed With or without food	Evening for skin or recovery contexts With or without food
Poziom dowodów	Badawcze	Badania kliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported by the source for topical cosmetic use.) Redness (Listed as rare.) Itching (Listed as rare.) +1 więcej Minimal systemic absorption (Reported in the source for topical use.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Podsumowanie researchu	The source highlights a 12-week double-blind, placebo-controlled split-face study in 93 women aged 35 to 55 that compared a Pal-KTTKS moisturizer with the same base moisturizer. It reports improvements in fine lines and wrinkles on the peptide-treated side with good tolerability. Laboratory evidence cited in the source points toward increased collagen I, collagen IV, and fibronectin synthesis. The source also cautions that large percentage claims often trace back to manufacturer or formulation data, so exact promotional figures should not be treated as settled clinical outcomes.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
Referencje	PubMed Wiley Online Library +1 więcej ResearchGateTopically applied KTTKS: a review	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Matrixyl

GHK-Cu

Kategoria

Skóra i włosy

Znany tez jako

Palmitoyl Pentapeptide-4, Pal-KTTKS

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Zatwierdzony przez FDA

Nie

Status kliniczny

Cosmetic use; extensively studied

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Collagen production, anti-aging, skin firmness

Skin rejuvenation, wound healing, hair growth, anti-aging

Jak dziala

Matrixyl is described as Pal-KTTKS, a palmitoylated form of a five-amino-acid collagen fragment. The KTTKS segment is presented as a matrikine-style signal associated with extracellular-matrix turnover, while the palmitoyl tail is used to improve compatibility with topical delivery through the outer skin barrier. The supplied evidence distinguishes this collagen-signaling model from muscle-targeting wrinkle approaches.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typowe dawkowanie

Limited community data available · See research protocols · Topical (serums, creams)

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Dawkowanie z badań

3-8% in formulations · 8-12 weeks for visible results, ongoing use · Topical (serums, creams)

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typowy czas trwania

8-12 weeks for visible results; ongoing use reported

Varies by application

Podanie

Topical skin application in serums or creams

Subcutaneous injection or topical application

Timing

Morning or as directed

With or without food

Evening for skin or recovery contexts

With or without food

Poziom dowodów

Badawcze

Badania kliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported by the source for topical cosmetic use.)
Redness (Listed as rare.)
Itching (Listed as rare.)

+1 więcej

Minimal systemic absorption (Reported in the source for topical use.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Podsumowanie researchu

The source highlights a 12-week double-blind, placebo-controlled split-face study in 93 women aged 35 to 55 that compared a Pal-KTTKS moisturizer with the same base moisturizer. It reports improvements in fine lines and wrinkles on the peptide-treated side with good tolerability. Laboratory evidence cited in the source points toward increased collagen I, collagen IV, and fibronectin synthesis. The source also cautions that large percentage claims often trace back to manufacturer or formulation data, so exact promotional figures should not be treated as settled clinical outcomes.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

Referencje

PubMed Wiley Online Library

+1 więcej

ResearchGateTopically applied KTTKS: a review

PubMed PubMed

+1 więcej

PubMed

Pełny profil

Zobacz szczegóły